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Human stem cell-derived β (SC-β) cells have the potential to revolutionize diabetes
treatment through disease modeling, drug screening, and cellular therapy. SC-β cells
are likely to represent an early clinical translation of differentiated human pluripotent
stem cells (hPSC). In 2014, two groups generated the first in vitro-differentiated glucoseresponsive SC-β cells, but their functional maturation at the time was low. This review
will discuss recent advances in the engineering of SC-β cells to understand and improve
SC-β cell differentiation and functional maturation, particularly new differentiation
strategies achieving dynamic glucose-responsive insulin secretion with rapid correction
to normoglycemia when transplanted into diabetic mice.
Keywords: stem cells, diabetes, differentiation, pluripotent, transplantation

INTRODUCTION
Diabetes mellitus can be characterized as a disease of the β cell, which results in improper
insulin secretion and failure to maintain normal glycemia. Type 1 diabetes (T1D) is the
result of the dysregulated autoimmune destruction of β cells (Gillespie, 2006). Type 2 diabetes
(T2D) is characterized by β cell malfunction and depletion due to high stress caused by
chronic hyperglycemia. Currently T1D and many T2D patients are reliant on exogenous insulin
treatment. Exogenous insulin treatment requires constant monitoring and injections throughout
the day, reducing quality of life and failing to accurately maintain normal glycemia leading
to secondary complications (Caro et al., 2002; Powers and D’Alessio, 2011). Transplantation
of whole pancreas or purified islets of Langerhans have been shown to result in exogenous
insulin independence with accurate glycemic regulation in T1D and T2D patients (Posselt et al.,
2010; Gruessner and Gruessner, 2016; Kandaswamy et al., 2018). Widespread application of islet
transplantation is limited by replacement tissue availability and the need for immunosuppression
(Millman and Pagliuca, 2017).
Human SC-β cells are a promising alternative cell source for diabetes cell replacement therapy as
well as disease modeling and drug screening (Millman and Pagliuca, 2017). In vitro differentiated
SC-β cells were first produced in 2014 (Pagliuca et al., 2014; Rezania et al., 2014). These early SCβ cells presented β cell hallmarks, such as insulin secretion in response to glucose, expression of
β cell transcription factors, and in vivo function in weeks after transplantation in mice. However,
critical differences remained between SC-β cells and primary adult β cells, including inferior insulin
secretion per cell, dysregulated glucose-stimulated insulin secretion (GSIS) dynamics, and lower
expression of key β cell transcription factors. Recent studies, discussed here, have significantly
advanced the functional maturity of SC-β cells resulting in functionally enhanced SC-β cells. These
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population. In addition to ALK5i and T3, Rezania includes
compounds R428, an AXL inhibitor, with N-acetyl cysteine,
claiming them to drive expression of β cell maturation
gene MAFA. The Rezania et al. air-liquid interface culture
format can be more easily replicated by laboratories with
standard culture experience and equipment, however it is
less scalable than the suspension culture format described in
Pagliuca et al. which requires more specialized equipment
and knowledge of 3D cell culture. These original SC-β cells
represented a monumental accomplishment being scalable,
glucose responsive, transcriptionally similar to primary islets,
and capable of regulating mouse blood glucose in weeks post
transplantation. Despite these accomplishments the resulting
SC-β cells were functionally immature, secreting low levels
of insulin, no dynamic insulin secretion, immature calcium
response, and transcriptional differences remained relative
to cadaveric islets with measurable differences in MAFA,
UCN3, and GCK gene expression (Pagliuca et al., 2014;
Rezania et al., 2014).

enhanced SC-β cells have improved function, with some
achieving dynamic insulin secretion marked by the presence of
first and second phase insulin secretion. Despite the enhancement
of these SC-β cells, they fail to match the glucose responsiveness
and transcriptomic profile of primary cadaveric islets (Baron
et al., 2016; Nair et al., 2019; Velazco-Cruz et al., 2019; Hogrebe
et al., 2020; Mahaddalkar et al., 2020). In this review we
describe the advancements made for achieving enhanced SC-β
cells and the path toward differentiating fully functional SC-β
cells resembling cadaveric islets in terms of their function and
transcriptomic profile.

THE PATH TOWARD SC-β CELLS
The path toward differentiating SC-β cells has proved
challenging, having already spanned over two decades.
Progress has occurred in waives as hard-fought milestones
are achieved. Early pioneering work established methodologies
for differentiating hPSCs toward definitive endoderm (D’Amour
et al., 2005), the first developmental stage in the path toward
making β cells. Further sequential treatments of growth
factors and small molecules continued to mimic pancreatic
organogenesis guiding hPSCs through stages resembling
definitive endoderm, gut-tube endoderm, pancreatic endoderm,
and ultimately hormone expressing endoderm. The resulting
insulin producing cells were polyhormonal, failed to maintain
PDX1 and NKX6.1 expression, and were not glucose responsive
(D’Amour et al., 2006). However, transplantation of hPSCderived pancreatic progenitors into immunocompromised mice
allowed for their differentiation into monohormonal glucosestimulated insulin-secreting cells after several months in vivo
(Kroon et al., 2008; Rezania et al., 2012). Since then, other groups
have demonstrated that PDX1 and NKX6.1 expressing pancreatic
progenitors have the potential of differentiating toward β cells
(Rezania et al., 2013; Schaffer et al., 2013; Nostro et al., 2015;
Millman et al., 2016).
In 2014, two protocols were published for the efficient
generation of glucose-responsive monohormonal in vitrodifferentiated SC-β cells (Pagliuca et al., 2014; Rezania et al.,
2014). These protocols generated pancreatic progenitors with
high PDX1, NKX6.1 and low NGN3 expression. Low NGN3
expression through Vitamin C treatment distinguishes these
pancreatic progenitors from earlier protocols (Kroon et al.,
2008; Rezania et al., 2012). These pancreatic progenitors
where then differentiated to hormone expressing endocrine
cells through transient NGN3 upregulation by treatment
with TGFβR1 inhibitor ALK5i Type II (ALK5i) and thyroid
hormone (T3). Air-liquid interface culture was observed to
increase NGN3 expression relative to planar culture (Rezania
et al., 2014) while the other protocol was completed in
suspension culture (Pagliuca et al., 2014). The continued
treatment of endocrine CHGA+ cells with ALK5i, T3, and
γ-secretase (XXI or XX) drives the endocrine population
toward monohormonal INS+ cells. The final stage of these
protocols cultured the cells with ALK5i and T3 resulting
in glucose responsive SC-β cells making up ∼40% of the

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org

ADVANCING SC-β CELLS
Early SC-β cells are functionally immature lacking dynamic
insulin secretion and observable functional maturation occurring
after transplantation in vivo, marked by an increase in
secreted insulin with time post transplantation (Pagliuca
et al., 2014; Rezania et al., 2014; Russ et al., 2015). More
functional SC-β cells are needed to improve cell replacement
outcomes and facilitate more robust disease modeling studies.
Recent publications have demonstrated improved differentiation
efficiency, higher glucose stimulated insulin secretion, first
and second phase insulin secretion, response to multiple
secretagogues, and fast in vivo glucose regulation upon
transplantation (Table 1; Nair et al., 2019; Velazco-Cruz
et al., 2019; Veres et al., 2019; Hogrebe et al., 2020;
Mahaddalkar et al., 2020).
Velazco-Cruz et al. was first to report robust dynamic
insulin secretion of SC-β cells (Velazco-Cruz et al., 2019)
with both first and second phase kinetics using a suspension
differentiation protocol with temporal TGFβ modulation, cellular
cluster size control, serum free media, endocrine enrichment
without cell selection, and a simplified final stage media
lacking notable prior factors (T3, N-acetyl cysteine, Trolox,
and R428). The authors show that treatment with TGFβR1
inhibitor, ALK5 inhibitor type II (ALK5i), is necessary for
specification of the β cell fate. However, upon β cell specification
permittance of TGFβ signaling is critical for SC-β cell
functional maturation. However, ALK5i is widely used in the
final stage of many β cell differentiation protocols (Pagliuca
et al., 2014). The authors show that by re-sizing cellular
clusters during the last stage of the differentiation, a process
which involves partial dissociation of clusters as previously
reported (Song and Millman, 2017), enhances static GSIS and
nearly doubles the C-Peptide+ NKX6.1+ co-expressing SC-β
cell population. In dynamic secretion assays, robust dynamic
function with a clear first phase, stable second phase, and
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Quantitative values estimated from graphs when not reported in text. N.R., not reported; S, suspension; P, planar; S#, stage #.
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a return to basal levels after high glucose treatment ends
was shown. However, a weakness of the study was that
insulin secretion per cell and the degree insulin secretion was
increased in response to high glucose varied across different
hPSC lines. Transplantation of these cells improved glucose
tolerance in mice.
Veres et al. employed some of the same changes as VelazcoCruz et al., including cellular cluster size control, serum
free media, endocrine enrichment without cell selection, and
a final stage media lacking T3, N-acetyl cysteine, Trolox,
and R428 (Veres et al., 2019). Additionally, Veres et al.
employs β cell enrichment using cell sorting. Through a
similar cellular reaggregation method, Veres et al. sees strong
endocrine enrichment and an increase in the frequency of
the C-Peptide+ /NKX6.1+ SC-β cell population along with
improved static GSIS. The authors further show that enrichment
of the β cell population through CD49a+ cell sorting improved
static GSIS relative to unsorted and reaggregated SC-β cells.
CD49a+ sorted cells demonstrated first and second phase
insulin secretion, however a return to basal levels did not
occur when high glucose was removed. The authors did
not show if reaggregated cells could undergo dynamic GSIS.
The authors identify enterochromaffin-like cells in their SCβ cell preps and CD49+ sorting removes these cell types.
Enterochromaffin cells, marked by TPH1 expression, secrete
serotonin in the gut and are absent from the human pancreas.
This study indicates β cells and enterochromaffin cells share
a similar developmental path resulting in their presence in
β cell differentiation protocols. It is unclear if the functional
benefits observed by CD49+ sorting are due to the removal
of off target cell types, such as enterochromaffin-like cells,
or other mechanisms. Transplantation into mice was not
investigated in this study.
In a separate study, Nair et al. achieved first phase insulin
secretion using an insulin-driven GFP tag cell sorting approach
and a reaggregation process (Nair et al., 2019). The authors
achieved a high β cell population with 80% C-Peptide/NKX6.1
co-expression. In functional studies the authors compare
reaggregated GFP enriched cells to un-reaggregated unsorted β
cell clusters, with limited functional studies using reaggregated
and unsorted clusters as a control. The authors see no first
phase response in the immature clusters or the reaggregated
and unsorted clusters while there GFP sorted reaggregated
clusters have a first phase stimulation index of ∼3 and no
second phase response. However, the study design did not
allow for distinguishing functional improvements related to
endocrine enrichment by reaggregation or β cell enrichment by
sorting, like done with CD49a enrichment (Veres et al., 2019).
This study was performed using only one insulin-driven GFP
reporter cell line, making it unclear how well this approach
would apply to other cell lines and whether the low levels of
insulin secretion are due to the genetic engineering or genetic
background of this cell line relative to other protocols. It is
important to note that this differentiation protocol retains ALK5i
and T3 during the final stage of differentiation, while other
enhanced SC-β cell protocols have removed them (RosadoOlivieri et al., 2019; Velazco-Cruz et al., 2019; Veres et al., 2019;
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TABLE 1 | Characteristics of Enhanced SC-β cell protocols.
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populations. Additionally, this work shows canonical WNT
inhibition by IWP2 treatment to increase pancreatic progenitor
differentiation efficiency, a finding supported by previous
publications (Loh et al., 2014; Davenport et al., 2016; Zhu
et al., 2016). Differentiation of CD177+ cells toward β
cells resulted in improved differentiation efficiency and
function relative to unsorted cells. CD177+ cells presented
a first phase insulin response with no second phase, while
unsorted cells did not present a first or second phase insulin
secretion (Mahaddalkar et al., 2020). The cells were not
transplanted into mice.
Direct comparison of these studies is difficult, as
assays evaluating function are variable, including technical
methodologies, normalization strategies, and in vivo models
differ. Normalizing SC-β cells to cadaveric human islet insulin
secretion is imperfect, as cadaveric islet function is highly
variable within and between studies (Pagliuca et al., 2014;
Nair et al., 2019; Velazco-Cruz et al., 2019; Veres et al., 2019).
Standardized static and dynamic GSIS assays, normalized
to DNA, can greatly facilitate comparison of differentiation
protocols while imposing minimal burden on investigators.
Standardization of in vivo assays are more challenging,
as many mouse and diabetic models exist with variable
severity of diabetes. By providing standardized in vitro
GSIS results, individual researchers can better compare
protocols and guide the differentiation protocols employed
in their studies.

Hogrebe et al., 2020; Maxwell et al., 2020). Therefore, it is possible
that removal of these compound will allow for more robust
dynamic secretion including the missing second phase observed
by this protocol. Transplantation of these cells improved glucose
tolerance in mice.
Hogrebe et al. (2020) used a different differentiation strategy
for generating SC-β cells, demonstrating that regulation of actin
cytoskeleton polymerization controls differentiation to endocrine
and other endodermal lineages. This insight led to development
of a planar β cell differentiation protocol. Other protocols use
suspension (Pagliuca et al., 2014; Russ et al., 2015; RosadoOlivieri et al., 2019; Velazco-Cruz et al., 2019; Veres et al., 2019)
or pseudo-suspension air-liquid interface (Rezania et al., 2014)
culture methodologies for endocrine specification, increasing
the technical expertise required for SC-β cell differentiations.
Using a novel planar differentiation protocol with actin
depolymerizer latrunculin A driving endocrine specification,
through neurogenin three upregulation, the authors generate SCβ cells which undergo dynamic GSIS. When these SC-β cells are
transplanted into mice, they rapidly reversed severe preexisting
diabetes at a rate resembling that achieved by cadaveric islets.
In a controlled and parallel fashion, Hogrebe et al. compared
his planar differentiated β cells to suspension differentiated β
cells using the Velazco-Cruz et al. protocol. Using the HUES8
cell line, for which the two protocols were optimized, the
suspension protocols had higher percent yields of CP+ NKX6.1+
SC-β cells. Functionally, planar and suspension derived SCβ cells were similar when assayed by static and dynamic
GSIS as well as insulin content. When assayed by real-time
PCR, the planar and suspension derived SC-β cells were
similar. An equal number of planar and suspension derived
SC-β cells were transplanted into diabetic mice. Diabetes
reversal with planar differentiated β cells occurred in two
weeks, while the suspension protocol took 5 weeks. This
discrepancy in diabetes cure speed is interesting, as in vitro
functional and transcriptomic assays did not show evident
differences between the two protocols and based on reported
differentiation efficiencies the suspension protocol generates a
higher proportion of SC-β cells. Single-cell RNA sequencing,
comparing transcriptomes of planar and suspension derived
SC-β cells could reveal further insights into the source of this
discrepancy. Importantly, the Hogrebe et al. planar protocol
was able to successfully differentiate SC-β cells from multiple
pluripotent stem cell lines, with some cell lines matching
cadaveric islets in function when assayed with dynamic perfusion
assays. While the HUES8 suspension and planar derived SCβ cells were functionally similar, the planar protocol yielded
higher functioning cells when applied to different cell lines. The
robustness of the planar Hogrebe et al. differentiation protocol
facilitates studies using more than one cell line (Maxwell et al.,
2020; Velazco-Cruz et al., 2020).
Using a sorting approach for CD177/NB1 glycoprotein,
Mahaddalkar et al. isolated anterior definitive endoderm cells
with increased pancreatic and β cell potential (Mahaddalkar
et al., 2020). The authors characterize CD177+ cells to have
increase PDX1 and NKX6.1 pancreatic progenitor potential
when compared to unsorted and CD275+ definitive endoderm
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FORGING A PATH FORWARD
Despite advances, current SC-β cells lack the functional
maturity of cadaveric islets. In the continuing quest to
functionally mature SC-β cells, teams are employing novel
technologies and approaches, such as single-cell sequencing,
genetic engineering, cell sorting, and drug screening, to identify
factors which contribute to β cell differentiation and function.
Recent publications have compared gene expression between
adult and fetal or juvenile islets, with many adult genes
having potential roles in the functional maturation of SC-β
cells. ERRγ has been characterized to be enriched in adult
vs neonatal mouse β cells and mice deficient of β cell
ERRγ fail to properly regulate their blood glucose (Yoshihara
et al., 2016). Yoshira et al. differentiates hPSCs toward an
immature β-like state in which many β cells genes are
expressed but are incapable of undergoing in vitro GSIS. The
authors overexpress ERRγ in these β-like cells and observed
improvements to mitochondrial respiration and the β-like cells
gain the ability to undergo in vitro GSIS. Upregulation of
ERRγ can potentially be used to further mature SC-β cells.
However, since its effects were only observed in immature
insulin-expressing endocrine cells incapable of undergoing
in vitro GSIS with immature mitochondrial respiration, it
may not translate to more advanced protocols which are
more metabolically mature (Nair et al., 2019). In a separate
study, Arda et al. shows islet function increases in adult
vs juvenile human islets identifying several genes associated
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with age in β cells including ONECUT2, MAFA, TSHZ3, SIX2,
and SIX3 (Arda et al., 2016). It remains to be investigated
whether upregulation of these genes in SC-β cells can drive their
functional maturation.
Inhibition of YAP signaling has been shown to drive
endocrine induction through neurogenin three upregulation
and when incorporated into differentiation protocols during
endocrine induction, using verteporfin, β differentiation
efficiency and function is enhanced (Rosado-Olivieri et al.,
2019). Dynamic function is not assayed in this work.
This work is supported by a previous study showing
pancreatic progenitor endocrinogenesis is stimulated by
YAP inhibition (Mamidi et al., 2018). Incorporation of YAP
inhibitors during endocrine specification and YAP agonist
during β cell maturation may drive improvements to β
cell generation.
Recent work (Ameri et al., 2017; Cogger et al., 2017; Nair
et al., 2019; Veres et al., 2019; Mahaddalkar et al., 2020)
has shown that enrichment of certain cell populations can
ultimately improve β cell differentiation efficiency and function.
Transcriptomic (Ameri et al., 2017) and proteomic (Cogger
et al., 2017) approaches have revealed glycoprotein two as
a cell surface marker beneficial for sorting PDX1+/NKX6.1+
pancreatic progenitors improving β cell differentiation efficiency.
Although functional improvements were not seen, this strategy
may increase the proportion of β cells generated using enhanced
differentiation protocols. Enrichment of the β cell population
through sorting may enhance the functional maturation of SCβ cells (Nair et al., 2019; Veres et al., 2019). Whether this
improvement is through cell-cell contact, paracrine signaling, or
the removal of inhibitory cell types, such as enterochromaffin
cells (Veres et al., 2019), remains to be determined with
more robust studies necessary. Cell enrichment using cell
sorting limits large scale production of SC-β cells. However,
the scale of production necessary for SC-β cells may be
compatible with magnetic-activated cell sorting approaches,
particularly as they have proven beneficial. Additionally,
identification of markers such as glycoprotein two can guide
the search for small molecules to increase the population
of cells expressing the desired markers. High throughput
screening for small molecules affecting differentiation has
been successful, with the identification of Rho-kinase inhibitor
H1152, capable of increasing MAFA and UCN3 expression
(Ghazizadeh et al., 2017).
Single-cell sequencing technologies are rapidly advancing
our understanding of β cell fate, differentiation, and functional
maturation. Several studies have increasingly elucidated the
β cell transcriptome (Baron et al., 2016; Segerstolpe et al.,
2016; Wang et al., 2016; Xin et al., 2016; Veres et al., 2019),
revealing novel β cell enriched genes which may be used as
markers for driving β cell functional maturation. Recently,
single-cell patch-clamp sequencing was used linking β cell
gene expression to functional phenotypes revealing sets of
genes correlating with β cell function (Camunas-Soler et al.,
2020). Veres et al. (2019) performed single-cell sequencing
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at multiple stages during SC-β cell differentiations revealing
transcriptomic profiles of each stage and genes whose expression
is correlated to the acquisition of function by SC-β cells.
Epigenome analysis of SC-β cell differentiation reveal LMX1B as
a regulator of endocrine specification and circadian rhythms as
a component toward SC-β cell functional maturation (AlvarezDominguez et al., 2020). These studies give researchers a more
accurate β cell transcriptomic model to guide differentiation
protocol development. To further advance SC-β cell technology,
researchers must continue efforts to build our understanding
of β cell development which guides development of β cell
differentiation protocols.

DISCUSSION
SC-β cells are a promising cell source for diabetes cell therapy,
disease modeling, and understanding human development.
The use of small molecules and growth factors to drive
stem cell differentiation toward β cells, mimicking in vivo
development, has proven a reliable strategy amenable to scaleup and genetic perturbations. Since the first fully in vitro
differentiation protocols (Pagliuca et al., 2014; Rezania et al.,
2014) capable of generating glucose responsive β cells, the
field has significantly advanced. Through the optimization
of differentiation protocols, including the removal of ALK5i
during the final stage of differentiation and reaggregation
driven endocrine enrichment, enhanced SC-β cells have greater
glucose responsiveness undergoing dynamic GSIS. Currently,
SC-β cells are still less functional than cadaveric islets secreting
lower amounts of insulin and a stable but lower in magnitude
second phase insulin secretion (Nair et al., 2019; Velazco-Cruz
et al., 2019; Veres et al., 2019). Transcriptionally, SC-β cells
resemble cadaveric islets more so than fetal islets, however critical
differences remain, such as reduced expression of maturation
factors MAFA and SIX3 (Veres et al., 2019). Using recently
published technologies and approaches our understanding of
β cell development is improving, guiding the development of
novel protocols capable of generating SC-β cells with function
matching that of primary islets. Generation of fully functionally
mature SC-β cells may be possible in the next few years and will
drive diabetes cell therapies forward while providing a robust
model for development and disease modeling.
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